Advertisement

Topics

Negotiations to Commercialize Noctiva in U.S. and Canada Underway

06:35 EDT 18 Aug 2017 | PharmPro

Avadel Pharmaceuticals enters into exclusive negotiations with Serenity Pharmaceuticals for Noctiva. If either company terminates negotiations without cause, it must pay the other $10 million. The exclusive period is expected to close on or before September 7.
Contributed Author: 
Avadel Pharmaceuticals plc
Topics: 

Original Article: Negotiations to Commercialize Noctiva in U.S. and Canada Underway

NEXT ARTICLE

More From BioPortfolio on "Negotiations to Commercialize Noctiva in U.S. and Canada Underway"

Advertisement
Quick Search
Advertisement
Advertisement